Cell hierarchy, metabolic flexibility and systems approaches to cancer treatment

Current Pharmaceutical Biotechnology

Volumn 14, Issue 3, 2013, Pages 289-299

  Herst, Patries M ^a   Berridge, Michael V ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

Author keywords

Cancer paradigms; Cell hierarchy; Drug targeting; Metabolic flexibility; Stem cells; Tissue organization

Indexed keywords

ALKYLATING AGENT; B RAF KINASE; BCR ABL PROTEIN; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LETROZOLE; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; N [3 (5 CHLORO 1H PYRROLO [2, 3 B] PYRIDINE 3 CARBONYL) 2, 4 DIFLUOROPHENYL] PROPANESULFONAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RETINOIC ACID; RITUXIMAB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VEMURAFENIB; WART VIRUS VACCINE;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EXPOSURE; ELECTRON TRANSPORT; ENERGY METABOLISM; HEPATITIS B; HUMAN; METASTATIC MELANOMA; MYELOID LEUKEMIA; NEOPLASM; NONHUMAN; OXIDATION REDUCTION STATE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASTICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR MICROENVIRONMENT; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; ENERGY METABOLISM; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84875285709     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201011314030005     Document Type: Article

References (132)

1. http://www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Statistics.2008.presentation.asp.
2. http://www.cancer.org/Research/CancerFactsFigures/cancerstatistics-2009-presentation, 2009.
3. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer, 2006, 6, 813-823.
4. Stuelten, C.; Mertins, S.; Busch, J.; Gowens, M.; Scudiero, D.; Burkett, M.; Hite, K.; Alley, M.; Hollingshead, M.; Shoemaker, R.; Niederhuber, J. Complex display of putative tumor stem cell markers in the NCI60 Tumor cell line panel. Stem Cells, 2010, 28, 649-660.
5. Pollak, M. N.; Schernhammer, E.S.; Hankinson, S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer, 2004, 4, 505-518.
6. Geschwind, J. F.; Ko, Y. H.; Torbenson, M. S.; Magee, C.; Pedersen, P. L. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res., 2002, 62, 3909-3913.
7. Bonnet, S.; Archer, S. L.; Allalunis-Turner, J.; Haromy, A.; Beaulieu, C.; Thompson, R.; Lee, C. T.; Lopaschuk, G. D.; Puttagunta, L.; Harry, G.; Hashimoto, K.; Porter, C. J.; Andrade, M. A.; Thebaud, B.; Michelakis, E. D. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 2007, 11, 37-51.
8. Fausel, C. Targeted chronic myeloid leukemia therapy: seeking a cure. J. Manag. Care Pharm., 2007, 13, 8-12.
9. Jorgensen, H. G.; Holyoake, T. L. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem. Soc. Trans., 2007, 35, 1347-1351.
10. Marin, D.; Marktel, S.; Bua, M.; Armstrong, L.; Goldman, J. M.; Apperley, J. F.; Olavarria, E. The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. Haematologica, 2002, 87, 979-988.
11. Hersey, P.; Bastholt, L.; Chiarion-Sileni, V.; Cinat, G.; Dummer, R.; Eggermont, A. M.; Espinosa, E.; Hauschild, A.; Quirt, I.; Robert, C.; Schadendorf, D. Small molecules and targeted therapies in distant metastatic disease. Ann. Oncol., 2009, 20, 35-40.
12. Michor, F.; Hughes, T. P.; Iwasa, Y.; Branford, S.; Shah, N. P.; Sawyers, C. L.; Nowak, M. A. Dynamics of chronic myeloid leukaemia. Nature, 2005, 435, 1267-1270.
13. Michor, F. Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells, 2007, 25, 1114-1118.
14. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; Sproesser, K.; Li, L.; Smalley, K. S.; Fong, D.; Zhu, Y. L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S. H.; Schlessinger, J.; Zhang, K. Y.; West, B. L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P. N.; Hirth, P.; Artis, D. R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA, 2008, 105, 3041-3046.
15. Halaban, R.; Zhang, W.; Bacchiocchi, A.; Cheng, E.; Parisi, F.; Ariyan, S.; Krauthammer, M.; McCusker, J. P.; Kluger, Y.; Sznol, M. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells. Pigment Cell Melanoma Res., 2010, 23, 190-200.
16. Heidorn, S. J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J. S.; Springer, C. J.; Pritchard, C.; Marais, R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell, 2010, 140, 209-221.
17. Dellapasqua, S.; Colleoni, M. Letrozole. Expert Opin Drug Metab. Toxicol., 2010, 6, 251-259.
18. Janni, W.; Hepp, P. Adjuvant aromatase inhibitor therapy: Outcomes and safety. Cancer Treat Rev., 2010, 36, 249-261.
19. Puhalla, S.; Brufsky, A.; Davidson, N. Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast, 2009, 18, S122-130.
20. Murdoch, D.; Sager, J. Will targeted therapy hold its promise? An evidence-based review. Curr. Opin. Oncol., 2008, 20, 104-111.
21. Campoli, M.; Ferris, R.; Ferrone, S.; Wang, X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin. Cancer Res., 2010, 16, 11-20.
22. Rosenberg, S. A.; Restifo, N. P.; Yang, J. C.; Morgan, R. A.; Dudley, M. E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer, 2008, 8, 299-308.
23. Banchereau, J.; Palucka, A. K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol., 2005, 5, 296-306.
24. Cerundolo, V.; Hermans, I. F.; Salio, M. Dendritic cells: a journey from laboratory to clinic. Nat. Immunol., 2004, 5, 7-10.
25. Palucka, A. K.; Ueno, H.; Fay, J.; Banchereau, J. Dendritic Cells: A Critical Player in Cancer Therapy? J. Immunother., 2008, 31, 793-805.
26. Neller, M. A.; Lopez, J. A.; Schmidt, C. W. Antigens for cancer immunotherapy. Semin. Immunol., 2008, 20, 286-295.
27. Degos, L.; Dombret, H.; Chomienne, C.; Daniel, M. T.; Miclea, J. M.; Chastang, C.; Castaigne, S.; Fenaux, P. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood, 1995, 85, 2643-2653.
28. Salih, H. R.; Kiener, P. A. Alterations in Fas (CD 95/Apo-1) and Fas ligand (CD178) expression in acute promyelocytic leukemia during treatment with ATRA. Leuk Lymphoma, 2004, 45, 55-59.
29. Kamashev, D.; Vitoux, D.; De The, H. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J. Exp. Med., 2004, 199, 1163-1174.
30. Lee, W.; Jiang, Z.; Liu, J.; Haverty, P. M.; Guan, Y.; Stinson, J.; Yue, P.; Zhang, Y.; Pant, K. P.; Bhatt, D.; Ha, C.; Johnson, S.; Kennemer, M. I.; Mohan, S.; Nazarenko, I.; Watanabe, C.; Sparks, A. B.; Shames, D. S.; Gentleman, R.; de Sauvage, F. J.; Stern, H.; Pandita, A.; Ballinger, D. G.; Drmanac, R.; Modrusan, Z.; Seshagiri, S.; Zhang, Z. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature, 2010, 465, 473-477.
31. Poage, G. M.; Christensen, B. C.; Houseman, E. A.; McClean, M. D.; Wiencke, J. K.; Posner, M. R.; Clark, J. R.; Nelson, H. H.; Marsit, C. J.; Kelsey, K. T. Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted. PLoS 2010, 5, e9651.
32. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A. Jr.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K.; Shinjo, S. M.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008, 321, 1807-1812.
33. Wood, L. D.; Parsons, D. W.; Jones, S.; Lin, J.; Sjoblom, T.; Leary, R. J.; Shen, D.; Boca, S. M.; Barber, T.; Ptak, J.; Silliman, N.; Szabo, S.; Dezso, Z.; Ustyanksky, V.; Nikolskaya, T.; Nikolsky, Y.; Karchin, R.; Wilson, P. A.; Kaminker, J. S.; Zhang, Z.; Croshaw, R.; Willis, J.; Dawson, D.; Shipitsin, M.; Willson, J. K.; Sukumar, S.; Polyak, K.; Park, B. H.; Pethiyagoda, C. L.; Pant, P. V.; Ballinger, D. G.; Sparks, A. B.; Hartigan, J.; Smith, D. R.; Suh, E.; Papadopoulos, N.; Buckhaults, P.; Markowitz, S. D.; Parmigiani, G.; Kinzler, K. W.; Velculescu, V. E.; Vogelstein, B. The genomic landscapes of human breast and colorectal cancers. Science, 2007, 318, 1108-1113.
34. Leary, R. J.; Lin, J. C.; Cummins, J.; Boca, S.; Wood, L. D.; Parsons, D. W.; Jones, S.; Sjoblom, T.; Park, B. H.; Parsons, R.; Willis, J.; Dawson, D.; Willson, J. K.; Nikolskaya, T.; Nikolsky, Y.; Kopelovich, L.; Papadopoulos, N.; Pennacchio, L. A.; Wang, T. L.; Markowitz, S. D.; Parmigiani, G.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. USA., 2008, 105, 16224-16229.
35. Bonnet, D.; Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 1997, 3, 730-737.
36. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414, 105-111.
37. Gupta, P. B.; Chaffer, C. L.; Weinberg, R. A. Cancer stem cells: mirage or reality? Nat. Med., 2009, 15, 1010-1012.
38. Visvader, J. E.; Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer, 2008, 8, 755-768.
39. Quintana, E.; Shackleton, M.; Sabel, M. S.; Fullen, D. R.; Johnson, T. M.; Morrison, S. J. Efficient tumour formation by single human melanoma cells. Nature, 2008, 456, 593-598.
40. Schatton, T.; Murphy, G. F.; Frank, N. Y.; Yamaura, K.; Waaga-Gasser, A. M.; Gasser, M.; Zhan, Q.; Jordan, S.; Duncan, L. M.; Weishaupt, C.; Fuhlbrigge, R. C.; Kupper, T. S.; Sayegh, M. H.; Frank, M. H. Identification of cells initiating human melanomas. Nature, 2008, 451, 345-349.
41. Boiko, A. D.; Razorenova, O. V.; van de Rijn, M.; Swetter, S. M.; Johnson, D. L.; Ly, D. P.; Butler, P. D.; Yang, G. P.; Joshua, B.; Kaplan, M. J.; Longaker, M. T.; Weissman, I. L. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature, 2010, 466, 133-137.
42. Roesch, A.; Fukunaga-Kalabis, M.; Schmidt, E. C.; Zabierowski, S. E.; Brafford, P. A.; Vultur, A.; Basu, D.; Gimotty, P.; Vogt, T.; Herlyn, M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell, 2010, 141, 583-594.
43. Abollo-Jimenez, F.; Jimenez, R.; Cobaleda, C. Physiological cellular reprogramming and cancer. Semin. Cancer Biol., 2010, 20, 98-106.
44. Red-Horse, K.; Ueno, H.; Weissman, I. L.; Krasnow, M. A. Coronary arteries form by developmental reprogramming of venous cells. Nature, 2010, 464, 549-553.
45. Thorel, F.; Nepote, V.; Avril, I.; Kohno, K.; Desgraz, R.; Chera, S.; Herrera, P. L. Conversion of adult pancreatic alpha-cells to betacells after extreme beta-cell loss. Nature, 2010, 464, 1149-1154.
46. Al-Hajj, M.; Wicha, M. S.; Benito-Hernandez, A.; Morrison, S. J.; Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA., 2003, 100, 3983-3988.
47. Li, C.; Heidt, D. G.; Dalerba, P.; Burant, C. F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M. F.; Simeone, D. M. Identification of pancreatic cancer stem cells. Cancer Res., 2007, 67, 1030-1037.
48. O'Brien, C. A.; Pollett, A.; Gallinger, S.; Dick, J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 2007, 445, 106-110.
49. Ricci-Vitiani, L.; Lombardi, D. G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and expansion of human colon-cancer-initiating cells. Nature, 2007, 445, 111-115.
50. Singh, S. K.; Clarke, I. D.; Terasaki, M.; Bonn, V. E.; Hawkins, C.; Squire, J.; Dirks, P. B. Identification of a cancer stem cell in human brain tumors. Cancer Res., 2003, 63, 5821-5828.
51. Wang, X.; Kruithof-de Julio, M.; Economides, K. D.; Walker, D.; Yu, H.; Halili, M. V.; Hu, Y. P.; Price, S. M.; Abate-Shen, C.; Shen, M. M. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature, 2009, 461, 495-500.
52. Sonveaux, P.; Vegran, F.; Schroeder, T.; Wergin, M. C.; Verrax, J.; Rabbani, Z. N.; De Saedeleer, C. J.; Kennedy, K. M.; Diepart, C.; Jordan, B. F.; Kelley, M. J.; Gallez, B.; Wahl, M. L.; Feron, O.; Dewhirst, M. W. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest., 2008, 118, 3930-3942.
53. Dewhirst, M. W.; Secomb, T. W.; Ong, E. T.; Hsu, R.; Gross, J. F. Determination of local oxygen consumption rates in tumors. Cancer Res., 1994, 54, 3333-3336.
54. Helmlinger, G.; Yuan, F.; Dellian, M.; Jain, R. K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med., 1997, 3, 177-182.
55. Raghunand, N.; Gatenby, R. A.; Gillies, R. J. Microenvironmental and cellular consequences of altered blood flow in tumours. Br. J. Radiol., 2003, 76, S11-22.
56. Ahn, G. O.; Brown, M. Targeting tumors with hypoxia-activated cytotoxins. Front Biosci., 2007, 12, 3483-3501.
57. Brown, J. M.; Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer, 2004, 4, 437-447.
58. Sattler, U. G.; Mueller-Klieser, W. The anti-oxidant capacity of tumour glycolysis. Int. J. Radiat. Biol., 2009, 85, 963-971.
59. Godinot, C.; de Laplanche, E.; Hervouet, E.; Simonnet, H. Actuality of Warburg's views in our understanding of renal cancer metabolism. J. Bioenerg. Biomembr., 2007, 39, 235-241.
60. Gatenby, R. A.; Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004, 4, 891-899.
61. Zu, X. L.; Guppy, M. Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys Res. Commun., 2004, 313, 459-465.
62. Denko, N. C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer, 2008, 8, 705-713.
63. Brahimi-Horn, C.; Pouyssegur, J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull. Cancer, 2006, 93, E73-80.
64. Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009, 324, 1029-1033.
65. Redout, E. M.; Wagner, M. J.; Zuidwijk, M. J.; Boer, C.; Musters, R. J.; van Hardeveld, C.; Paulus, W. J.; Simonides, W. S. Rightventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species. Cardiovasc. Res., 2007, 75, 770-781.
66. Zhang, L.; Yu, L.; Yu, C. A. Generation of superoxide anion by succinate-cytochrome c reductase from bovine heart mitochondria. J. Biol. Chem., 1998, 273, 33972-33976.
67. Birnbaum, M. J.; Haspel, H. C.; Rosen, O. M. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science, 1987, 235, 1495-1498.
68. Flier, J. S.; Mueckler, M. M.; Usher, P.; Lodish, H. F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science, 1987, 235, 1492-1495.
69. Reske, S. N.; Grillenberger, K. G.; Glatting, G.; Port, M.; Hildebrandt, M.; Gansauge, F.; Beger, H. G. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J. Nucl. Med., 1997, 38, 1344-1348.
70. Mamede, M.; Higashi, T.; Kitaichi, M.; Ishizu, K.; Ishimori, T.; Nakamoto, Y.; Yanagihara, K.; Li, M.; Tanaka, F.; Wada, H.; Manabe, T.; Saga, T. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia, 2005, 7, 369-379.
71. Macheda, M. L.; Rogers, S.; Best, J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol., 2005, 202, 654-662.
72. Kunkel, M.; Reichert, T. E.; Benz, P.; Lehr, H. A.; Jeong, J. H.; Wieand, S.; Bartenstein, P.; Wagner, W.; Whiteside, T. L. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer, 2003, 97, 1015-1124.
73. Fiorentini, D.; Prata, C.; Maraldi, T.; Zambonin, L.; Bonsi, L.; Hakim, G.; Landi, L. Contribution of reactive oxygen species to the regulation of Glut1 in two hemopoietic cell lines differing in cytokine sensitivity. Free Radic. Biol. Med., 2004, 37, 1402-1411.
74. Ahmed, N.; Berridge, M. V. Transforming oncogenes regulate glucose transport by increasing transporter affinity for glucose: contrasting effects of oncogenes and heat stress in a murine marrow-derived cell line. Life Sci., 1998, 63, 1887-1903.
75. Ahmed, N.; Berridge, M. V. Distinct regulation of glucose transport by interleukin-3 and oncogenes in a murine bone marrowderived cell line. Biochem. Pharmacol., 1999, 57, 387-396.
76. Berridge, M. V.; Tan, A. S. Interleukin-3 facilitates glucose transport in a myeloid cell line by regulating the affinity of the glucose transporter for glucose: involvement of protein phosphorylation in transporter activation. Biochem. J., 1995, 305, 843-851.
77. McCoy, K. D.; Ahmed, N.; Tan, A. S.; Berridge, M. V. The hemopoietic growth factor, interleukin-3, promotes glucose transport by increasing the specific activity and maintaining the affinity for glucose of plasma membrane glucose transporters. J. Biol. Chem., 1997, 272, 17276-17282.
78. Nefesh, I.; Bauskin, A. R.; Alkalay, I.; Golembo, M.; Ben-Neriah, Y. IL-3 facilitates lymphocyte hexose transport by enhancing the intrinsic activity of the transport system. Int. Immunol., 1991, 3, 827-831.
79. Palit, V.; Phillips, R. M.; Puri, R.; Shah, T.; Bibby, M. C. Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol. Rep., 2005, 14, 909-913.
80. Facey, K.; Bradbury, I.; Laking, G.; Payne, E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol. Assess, 2007, 11, iii-iv, xi-267.
81. Wahl, R. L.; Jacene, H.; Kasamon, Y.; Lodge, M. A. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med., 2009, 50, 122S-150S.
82. Elstrom, R. L.; Tsai, D. E.; Vergilio, J. A.; Downs, L. H.; Alavi, A.; Schuster, S. J. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow. Clin. Lymphoma, 2004, 5, 62-64.
83. Mathupala, S. P.; Rempel, A.; Pedersen, P. L. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J. Bioenerg. Biomembr., 1997, 29, 339-343.
84. Robbins, R. J.; Wan, Q.; Grewal, R. K.; Reibke, R.; Gonen, M.; Strauss, H. W.; Tuttle, R. M.; Drucker, W.; Larson, S. M. Realtime prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J. Clin. Endocrinol. Metab., 2006, 91, 498-505.
85. Herst, P. M.; Berridge, M. V. Plasma membrane electron transport: a new target for cancer drug development. Curr. Mol. Med., 2006, 6, 895-904.
86. Fantin, V. R.; St-Pierre, J.; Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006, 9, 425-434.
87. Warburg, O. On the origin of cancer cells. Science, 1956, 123, 309-314.
88. Pedersen, P. L. Tumor mitochondria and the bioenergetics of cancer cells. Prog. Exp. Tumor. Res., 1978, 22, 190-274.
89. Schornack, P. A.; Gillies, R. J. Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia, 2003, 5, 135-145.
90. Berridge, M. V.; Tan, A. S. High-capacity redox control at the plasma membrane of mammalian cells: trans-membrane, cell surface, and serum NADH-oxidases. Antiox. Redox Signal., 2000, 2, 231-242.
91. del Castillo-Olivares, A.; Nunez de Castro, I.; Medina, M. A. Dual role of plasma membrane electron transport systems in defense. Crit. Rev. Biochem. Mol. Biol., 2000, 35, 197-220.
92. Crane, F. L.; Sun, I. L.; Barr, R.; Low, H. Electron and proton transport across the plasma membrane. J. Bioenerg. Biomembr., 1991, 23, 773-803.
93. Herst, P. M.; Berridge, M. V. Cell surface oxygen consumption: a major contributor to cellular oxygen consumption in glycolytic cancer cell lines. Biochim. Biophys. Acta, 2007, 1767, 170-177.
94. Larm, J. A.; Vaillant, F.; Linnane, A. W.; Lawen, A. Up-regulation of the plasma membrane oxidoreductase as a prerequisite for the viability of human Namalwa rho 0 cells. J. Biol. Chem., 1994, 269, 30097-30100.
95. Berridge, M. V.; Tan, A. S. Trans-plasma membrane electron transport: a cellular assay for NADH-and NADPH-oxidase based on extracellular, superoxide-mediated reduction of the sulfonated tetrazolium salt WST-1. Protoplasma, 1998, 205, 74-82.
96. Herst, P. M.; Tan, A. S.; Scarlett, D. J.; Berridge, M. V. Cell surface oxygen consumption by mitochondrial gene knockout cells. Biochim. Biophys. Acta, 2004, 1656, 79-87.
97. Berridge, M. V.; Herst, P. M.; Tan, A. S. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol. Ann. Rev., 2005, 11, 127-152.
98. Scarlett, D.-J. G.; Herst, P. M.; Tan, A. S.; Prata, C.; Berridge, M. V. Mitochondrial gene-knockout (r°) cells: a versatile model for exploring the secrets of trans-plasma membrane electron transport. Biofactors, 2004, 20, 213-220.
99. Tan, A. S.; Berridge, M. V. Distinct trans-plasma membrane redox pathways reduce cell-impermeable dyes in HeLa cells. Redox Rep., 2004, 9, 302-306.
100. Morre, D. J.; Morre, D. M. Cell surface NADH oxidases (ECTONOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases. Free Radic. Res., 2003, 37, 795-808.
101. Scarlett, D. J.; Herst, P. M.; Berridge, M. V. Multiple proteins with single activities or a single protein with multiple activities: the conundrum of cell surface NADH oxidoreductases. Biochim. Biophys Acta, 2005, 1708, 108-119.
102. Unwin, R. D.; Craven, R. A.; Harnden, P.; Hanrahan, S.; Totty, N.; Knowles, M.; Eardley, I.; Selby, P. J.; Banks, R. E. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics, 2003, 3, 1620-1632.
103. Kulawiec, M.; Safina, A.; Desouki, M. M.; Still, I.; Matsui, S.; Bakin, A.; Singh, K. K. Tumorigenic transformation of human breast epithelial cells induced by mitochondrial DNA depletion. Cancer Biol. Ther., 2008, 7, 1732-1743.
104. Berridge, M. V.; Tan, A. S. Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res., 2009, 13, 139-141.
105. Hoek, K. S.; Eichhoff, O. M.; Schlegel, N. C.; Dobbeling, U.; Kobert, N.; Schaerer, L.; Hemmi, S.; Dummer, R. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res., 2008, 68, 650-656.
106. Yu, M.; Shi, Y.; Wei, X.; Yang, Y.; Zhou, Y.; Hao, X.; Zhang, N.; Niu, R. Depletion of mitochondrial DNA by ethidium bromide treatment inhibits the proliferation and tumorigenesis of T47D human breast cancer cells. Toxicol. Lett., 2007, 170, 83-93.
107. Indo, H. P.; Davidson, M.; Yen, H. C.; Suenaga, S.; Tomita, K.; Nishii, T.; Higuchi, M.; Koga, Y.; Ozawa, T.; Majima, H. J. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion, 2007, 7, 106-118.
108. Andreani, A.; Burnelli, S.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Varoli, L.; Landi, L.; Prata, C.; Berridge, M. V.; Grasso, C.; Fiebig, H. H.; Kelter, G.; Burger, A. M.; Kunkel, M. W. Antitumor activity of bis-indole derivatives. J. Med. Chem., 2008, 51, 4563-4570.
109. Prata, C.; Grasso, C.; Loizzo, S.; Sega, F. V.; Caliceti, C.; Zambonin, L.; Fiorentini, D.; Hakim, G.; Berridge, M. V.; Landi, L. Inhibition of trans-plasma membrane electron transport: A potential anti-leukemic strategy. Leuk Res., 2010, Mar 22. [Epub ahead of print].
110. De Luca, T.; Morre, D. M.; Zhao, H.; Morre, D. J. NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. Biofactors, 2005, 25, 43-60.
111. Dumitru, C. A.; Gulbins, E. TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis. Oncogene, 2006, 25, 5612-5625.
112. Cardenas-Navia, L. I.; Mace, D.; Richardson, R. A.; Wilson, D. F.; Shan, S.; Dewhirst, M. W. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res., 2008, 68, 5812-5819.
113. Hoek, K. S.; Schlegel, N. C.; Eichhoff, O. M.; Widmer, D. S.; Praetorius, C.; Einarsson, S. O.; Valgeirsdottir, S.; Bergsteinsdottir, K.; Schepsky, A.; Dummer, R.; Steingrimsson, E. Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res., 2008, 21, 665-676.
114. Smolkova, K.; Bellance, N.; Scandurra, F.; Genot, E.; Gnaiger, E.; Plecita-Hlavata, L.; Jezek, P.; Rossignol, R. Mitochondrial bioenergetic adaptations of breast cancer cells to aglycemia and hypoxia. J. Bioenerg. Biomembr., 2010, 42, 55-67.
115. Hirsch, H. A.; Iliopoulos, D.; Tsichlis, P. N.; Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res., 2009, 69, 7507-7511.
116. Guzman, M. L.; Rossi, R. M.; Neelakantan, S.; Li, X.; Corbett, C. A.; Hassane, D. C.; Becker, M. W.; Bennett, J. M.; Sullivan, E.; Lachowicz, J. L.; Vaughan, A.; Sweeney, C. J.; Matthews, W.; Carroll, M.; Liesveld, J. L.; Crooks, P. A.; Jordan, C. T. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 2007, 110, 4427-4435.
117. Jezek, P.; Plecita-Hlavata, L.; Smolkova, K.; Rossignol, R. Distinctions and similarities of cell bioenergetics and the role of mitochondria in hypoxia, cancer, and embryonic development. Int. J. Biochem. Cell Biol., 2010, 42, 604-622.
118. Moreno-Sanchez, R.; Rodriguez-Enriquez, S.; Saavedra, E.; Marin-Hernandez, A.; Gallardo-Perez, J. C. The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells? Biofactors., 2009, 35, 209-225.
119. de Groof, A. J.; te Lindert, M. M.; van Dommelen, M. M.; Wu, M.; Willemse, M.; Smift, A. L.; Winer, M.; Oerlemans, F.; Pluk, H.; Fransen, J. A.; Wieringa, B. Increased OXPHOS activity precedes rise in glycolytic rate in H-RasV12/E1A transformed fibroblasts that develop a Warburg phenotype. Mol. Cancer, 2009, 8, 54.
120. Funes, J. M.; Quintero, M.; Henderson, S.; Martinez, D.; Qureshi, U.; Westwood, C.; Clements, M. O.; Bourboulia, D.; Pedley, R. B.; Moncada, S.; Boshoff, C. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc. Natl. Acad. Sci. USA., 2007, 104, 6223-6228.
121. Schatton, T.; Frank, N. Y.; Frank, M. H. Identification and targeting of cancer stem cells. Bioessays, 2009, 31, 1038-1049.
122. Gupta, P. B.; Onder, T. T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R. A.; Lander, E. S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 2009, 138, 645-659.
123. Guzman, M. L.; Rossi, R. M.; Karnischky, L.; Li, X.; Peterson, D. R.; Howard, D. S.; Jordan, C. T. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood, 2005, 105, 4163-4169.
124. Kawasaki, B. T.; Hurt, E. M.; Kalathur, M.; Duhagon, M. A.; Milner, J. A.; Kim, Y. S.; Farrar, W. L. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. Prostate, 2009, 69, 827-837.
125. Zhou, J.; Zhang, H.; Gu, P.; Bai, J.; Margolick, J. B.; Zhang, Y. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res. Treat., 2008, 111, 419-427.
126. Guzman, M. L.; Li, X.; Corbett, C. A.; Rossi, R. M.; Bushnell, T.; Liesveld, J. L.; Hebert, J.; Young, F.; Jordan, C. T. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood, 2007, 110, 4436-4344.
127. Deng, T.; Liu, J. C.; Pritchard, K. I.; Eisen, A.; Zacksenhaus, E. Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene. Clin. Cancer Res., 2009, 15, 119-130.
128. Evans, J. M.; Donnelly, L. A.; Emslie-Smith, A. M.; Alessi, D. R.; Morris, A. D. Metformin and reduced risk of cancer in diabetic patients. BMJ, 2005, 330, 1304-1305.
129. Jiralerspong, S.; Palla, S. L.; Giordano, S. H.; Meric-Bernstam, F.; Liedtke, C.; Barnett, C. M.; Hsu, L.; Hung, M. C.; Hortobagyi, G. N.; Gonzalez-Angulo, A. M. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol., 2009, 27, 3297-3302.
130. Larsson, S. C.; Mantzoros, C. S.; Wolk, A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int. J. Cancer, 2007, 121, 856-862.
131. Hardie, D. G. Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Lett., 2008, 582, 81-89.
132. Kalender, A.; Selvaraj, A.; Kim, S. Y.; Gulati, P.; Brule, S.; Viollet, B.; Kemp, B. E.; Bardeesy, N.; Dennis, P.; Schlager, J. J.; Marette, A.; Kozma, S. C.; Thomas, G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell, 2010, 11, 390-401.